"Oddział Onkologii Klinicznej i Chemioterapii Europejskie Centrum Zdrowia Otwock"
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Szczylik, Cezary
ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Checkmark Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate Enobosarm Versus Active Control for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer in Patients Who Previously Received an Estrogen Blocking Agent and a CDK 4/6 inhibitor
Checkmark TiP. Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking.…
Recruiting
3
210
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
03/23
04/23
postMONARCH, NCT05169567: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Checkmark postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy.
Recruiting
3
350
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
08/23
02/26
Jackiewicz-Papierowska, Marta
ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Checkmark Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate Enobosarm Versus Active Control for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer in Patients Who Previously Received an Estrogen Blocking Agent and a CDK 4/6 inhibitor
Checkmark TiP. Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking.…
Recruiting
3
210
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
03/23
04/23

Download Options